Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Key Resources and Organizations for Precision Medicine Guidelines

MedGenome Strengthens Leadership Team to Drive North American Expansion in Precision Medicine

NCCN Expands Clinical Practice Guidelines for High-Risk Genetic Cancer Assessment

Home
/
update
/
details

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

NextEdge Admin

09 Nov 2024

2 min 15 sec

Cancer52,whole genome sequencing,roundtable

Genomics England and Cancer52 recently held a roundtable with Cancer52’s member charities, focusing on genomics for rare and less common cancers. Cancer52, which represents over 115 UK patient groups, surveyed members, revealing low awareness about whole genome sequencing (WGS) and its benefits for these cancer types. The roundtable underscored the need for collaboration, patient involvement, and increased awareness in genomics research and testing.

Discussions highlighted the potential of WGS data for early detection, tailored treatments, and advancing research. Genomics England’s Cancer 2.0 programme was showcased, featuring promising technology like long read sequencing, which reads longer DNA fragments than older methods, offering new insights and potentially more accurate diagnoses and treatment options.

Key challenges include inequalities in genomic access across ethnic and geographic lines. Dr. Nicky Huskens, CEO of Tessa Jowell Brain Cancer Mission, shared findings from their *Equity in Genomics* report and ongoing efforts to improve clinical trials and genomic testing training for brain cancers. This, along with insights from Cancer52’s Sasha Daly and Sarcoma UK's Dr. Sorrel Bickley, highlighted the need for addressing access gaps.

The event stressed that collaboration, patient stories, and shared data are critical. To advance genomic integration in cancer care, sustained collaboration across research, clinical settings, patient groups, and funders is essential. Cancer52 and Genomics England’s joint efforts revealed vital insights for rare cancer communities, emphasizing genomics' present and future impact.